Theriva Biologics has acquired 1 company, including 1 in the last 5 years.
Theriva Biologics’ largest acquisition to date was in 2021, when it acquired VCN Biosciences S.L. for $75M. The Company’s most targeted sectors include life science (100%).
9605 Medical Center Drive, Suite 270,
Rockville, Maryland
20850
United States,
(301) 417-4364
www.therivabio.com
| Date | Target |
Value
$mlns |
Transaction Type | Acquirer | Seller |
SRC
Link |
|---|---|---|---|---|---|---|
| 2021-12-14 |
VCN · Life Science
Barcelona, Spain · www.vcnbiosciences.com VCN is a clinical-stage biotech company focused on developing a new oncolytic adenovirus (OV) platform designed for intravenous (IV) and intravitreal (IVit) delivery to trigger tumor cell death, improve access of co-administered cancer therapies to the tumor, and promote a robust and sustained anti-tumor response by the patient’s immune system. VCN is based in Barcelona, Spain. |
75 | Divestiture |
Grifols
|
Unlimited Searches Unlimited Profile Views Build and Export Lists of
Mergr is a user-friendly database designed to simplify the complex world of private equity and M&A for busy professionals.
We created Mergr to eliminate the challenge of tracking company acquisitions, sales, and ownership, providing clear insights into investment firms and their activities. For example, explore an investment firm’s investment criteria, deal history, portfolio, and connections - organized to help you uncover opportunities and make informed decisions.
With Mergr, gain access to a comprehensive, interconnected web of transactions, investors, companies, and advisors - all in one place.
Full access to Mergr's investor, acquirer, and transaction data starts here.
